Investing

Orbimed Advisors Now Owns 11.2% of Gracell Biotechnologies

howtogoto / iStock via Getty Images

Fintel reports that Orbimed Advisors has filed a 13D form with the SEC disclosing ownership of 7.58MM shares of Gracell Biotechnologies Inc. (GRCL). This represents 11.2% of the company.

In their previous filing dated February 14, 2023 they reported 5.97MM shares and 8.80% of the company, an increase in shares of 27.01% and an increase in total ownership of 2.40% (calculated as current – previous percent ownership).

Analyst Price Forecast Suggests 596.89% Upside

As of March 30, 2023, the average one-year price target for Gracell Biotechnologies is $12.82. The forecasts range from a low of $7.07 to a high of $21.00. The average price target represents an increase of 596.89% from its latest reported closing price of $1.84.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Gracell Biotechnologies is $0MM, a decrease of ?%. The projected annual non-GAAP EPS is -$0.59.

What is the Fund Sentiment?

There are 52 funds or institutions reporting positions in Gracell Biotechnologies. This is a decrease of 1 owner(s) or 1.89% in the last quarter. Average portfolio weight of all funds dedicated to GRCL is 0.11%, an increase of 29.14%. Total shares owned by institutions decreased in the last three months by 0.29% to 31,832K shares.

What are Large Shareholders Doing?

Temasek Holdings holds 9,902K shares representing 14.63% ownership of the company. No change in the last quarter.

EcoR1 Capital holds 3,343K shares representing 4.94% ownership of the company. In it’s prior filing, the firm reported owning 1,921K shares, representing an increase of 42.53%. The firm increased its portfolio allocation in GRCL by 28.16% over the last quarter.

Capital International holds 2,943K shares representing 4.35% ownership of the company. In it’s prior filing, the firm reported owning 3,016K shares, representing a decrease of 2.50%. The firm decreased its portfolio allocation in GRCL by 32.66% over the last quarter.

Great Point Partners holds 1,962K shares representing 2.90% ownership of the company. In it’s prior filing, the firm reported owning 449K shares, representing an increase of 77.12%. The firm increased its portfolio allocation in GRCL by 154.09% over the last quarter.

EMRGX – EMERGING MARKETS GROWTH FUND INC Class M holds 1,336K shares representing 1.97% ownership of the company. In it’s prior filing, the firm reported owning 1,368K shares, representing a decrease of 2.36%. The firm decreased its portfolio allocation in GRCL by 36.27% over the last quarter.

This article originally appeared on Fintel

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE

Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here
you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.


Click here
to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.